Pennsylvania-based Cephalon Inc., which has a manufacturing facility in Salt Lake City, has received U.S. Food and Drug Administration approval to market a sugar-free formulation of its Actiq drug.
The new product will be launched in the first half of 2006.
Actiq contains medication used to treat "breakthrough" cancer pain. It is a single-use lozenge, attached to a handle, which delivers the medicine.
Cephalon has about 2,300 employees worldwide.
What You May Have Missed
Most Popular
Across Site
In Business
- Wasting Money: Designer pet clothing and 59...
- Studies try to find why poorer people are...
- Top 10 poorest states in America
- 18 cheap ways to captivate teens
- Law school grad pays off $114,460 in debt...
- House GOP plans summer tax cut vote
- West Jordan teen releases 5th iPhone app
- KSL TV news icon Bruce Lindsay calls it a career
Most Commented
Across Site
In Business
- Billboard battle heats up as company...
29 - Utah County cities, businesses claim...
15 - Dangerous debt?: consumer advocate...
13 - Studies try to find why poorer people...
13 - KSL TV news icon Bruce Lindsay calls it...
12 - Millennials love to spend money they...
11 - Rising health care costs burden families
10 - 'Greecing' the wheels: U.S. financial...
10






DeseretNews.com encourages a civil dialogue among its readers. We welcome your thoughtful comments.
— About comments